Sunrun (NASDAQ:RUN) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $(0.05) by 680 percent. This is a 252.63 percent increase over losses of $(0.19) per share from the same period last year.
Improved Transplant-Free Survival Observed With Obeticholic Acid In People With Primary Biliary Cholangitis Published In Gastroenterology
Combined clinical trial and real-world data with six years of follow-up provides important evidence of efficacy
Analysis compares findings from the Phase 3 POISE trial and open-label extension to natural history
